IT0003828271

RECORDATI:  MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY Milan, 30 November 2020 – Recordati

RECORDATI:  MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY Milan, 30 November 2020 – Recordati

RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES –0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3% Consolidated revenues

RECORDATI:  MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED Reverse merger by absorption of

RECORDATI:  MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED Reverse merger by absorption of

RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION Milan, 21 September, 2020 – Recordati announces the

RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8% Consolidated revenues € 760.2 million,

RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE Isturisa® (osilodrostat) demonstrates significant and sustained